CBAY CymaBay Therapeutics Inc

CymaBay Therapeutics Inc is an American biotechnology enterprise. Its product candidates include Arhalofenate, MBX-8025, and MBX-2982, which are meant to combat serious metabolic diseases.

$3.93  0.00 (0.00%)
As of 12/08/2022 15:59:58 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/27/2014
Outstanding shares:  84,677,939
Average volume:  422,278
Market cap:   $342,945,653
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BJ3WDH3
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy